Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin as Pre-ASCT Induction in IGEV-Refractory Hodgkin Lymphoma
NCT02244021Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Complete Response Rate at 1.5 years. Started Dec 2014; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02244021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02244021.